How the choice between OATS and OCA is made

Choosing between osteochondral autograft transfer (OATS) and osteochondral allograft transplantation (OCA) rarely comes down to one technique being better than the other. The decision follows a clear clinical hierarchy — led by lesion size, then modified by the condition of the underlying bone and the patient's surgical history — so the right answer is different for different knees.

In plain terms: OATS uses cylindrical bone-and-cartilage plugs harvested from a low-load area of the patient's own knee and press-fitted into the defect; OCA uses a size-matched plug of fresh donor tissue shaped precisely to the repair site. Both restore hyaline cartilage to the defect, which is what distinguishes them from marrow-stimulation methods such as microfracture, where healing produces structurally inferior fibrocartilage that tends to break down over time.

That shared advantage places both procedures on the same rung of the cartilage-repair ladder — above marrow stimulation — but they serve different lesion profiles. How size sets the primary threshold, and which clinical factors can override it, is where the practical guidance begins.

Why both techniques differ from microfracture

Microfracture was for many years the standard first response to full-thickness cartilage damage in the knee. The technique works by breaching the subchondral bone plate to release marrow cells, which fill the defect — but the tissue that forms is fibrocartilage, a weaker substitute that typically begins to fail within two to three years under load.

The concern extends beyond durability. Each time marrow stimulation is performed, the subchondral bone plate sustains damage. Repeated procedures — or a revision after a failed first attempt — can permanently alter that bone layer, narrowing what remains surgically possible for future repair.

OATS and OCA take a different route: instead of encouraging the body to fill a void, both transplant complete osteochondral units — bone and cartilage together — so the repair site receives tissue that closely resembles the original structure from the outset.

Both procedures are suited to focal, full-thickness lesions (broadly ICRS grade III–IV) rather than the widespread joint-surface loss seen in established osteoarthritis, where neither is appropriate. That scope matters: this is a targeted repair option for discrete defects in an otherwise reasonable joint.

Lesion size: the starting point for every decision

Defect surface area is where the clinical conversation always begins. For OATS, a single plug can reliably address a focal lesion up to roughly 2 cm² — approximately the area of a small fingernail. Using multiple plugs in a mosaicplasty pattern extends that ceiling to around 4 cm², but the technique remains constrained by a hard physical limit: there are only so many low-load areas on the patient's own knee from which cartilage can be safely harvested without causing a new problem at the donor site.

The 2024 international Delphi consensus (Mills et al.) refined this guidance further, specifying OATS as the preferred option for isolated full-thickness lesions of ≤1.44 cm² (≤12 mm × 12 mm), based on ≥80% expert agreement. That figure is a consensus threshold, not a rigid rule; an experienced surgeon will weigh it alongside lesion geometry, depth, and the individual patient's anatomy.

Once a defect moves beyond the OATS range — broadly into the 2–10 cm² territory and beyond — OCA becomes the natural choice, because fresh donor tissue carries no equivalent size constraint. The graft is shaped precisely to the defect, regardless of area.

Anatomically, the medial femoral condyle is the most common site for the type of focal defect that both procedures address, accounting for the largest single location group across published surgical series.

Size, then, is the entry point — but two additional factors can override it entirely in certain knees, as the next section outlines.

When bone loss or surgical history shifts the decision

Two clinical findings can push the decision firmly towards OCA regardless of defect area: the condition of the bone beneath the cartilage, and what has been attempted surgically before.

When the underlying bone is damaged

Cartilage sits on a layer of specialised bone — the subchondral plate — which provides mechanical support and contributes to the nutrition of the joint surface. In some patients, particularly those with longer-standing lesions or osteochondritis dissecans, that bone layer is no longer intact. A surface-only repair with an autograft plug cannot adequately restore what lies underneath. OCA addresses this directly: the fresh allograft carries both the cartilage layer and a measured depth of bone, reconstructing the full osteochondral unit in one procedure.

When a previous cartilage operation has failed

As noted earlier in this article, marrow stimulation leaves the subchondral bone plate altered. For a patient who has already undergone microfracture, ACI, or a prior mosaicplasty that has not held, repeating a marrow-stimulation approach risks further damage to that foundation. OCA is the recognised salvage option in this setting — it brings new tissue rather than asking a compromised substrate to regenerate again.

Patient profile and joint mechanics

Beyond anatomy, a surgeon will consider the joint as a whole. OATS is typically suited to younger active patients — broadly under 40 to 45 — without a history of knee cartilage surgery, though this is a common profile rather than a rigid age cutoff. OCA candidates also tend to be younger and active, and the joint must have neutral or correctable limb alignment and intact ligamentous stability to give the graft a reasonable mechanical environment. Where alignment is off, an osteotomy may be planned alongside OCA to offload the repaired compartment — though that is a separate procedural consideration. Relative contraindications to OCA include significant obesity, advancing age, and lesions on both opposing joint surfaces, where the mechanical environment is unlikely to support graft survival.

Practical differences: recovery, risks, and logistics

For many patients, the most pressing questions are not about defect size in square centimetres but about what surgery actually involves day to day — whether the surgeon will harvest tissue from elsewhere in their knee, and how long recovery takes.

Donor-site morbidity with OATS

Because OATS uses the patient's own cartilage, a small area of the knee — typically a lower-load region of the femoral condyle — must serve as the harvest site. In most cases this causes no lasting problem, but donor-site morbidity is a recognised risk rather than a theoretical one. Adult-population estimates reach approximately 7.8%; a paediatric study found that 13.5% of OATS patients required a further knee procedure for fibrocartilage overgrowth at the harvest site, compared with none in the OCA group. These remain minority outcomes, but they are worth factoring into the conversation.

Scheduling and recovery with OCA

OCA avoids creating a new defect in the patient's knee entirely, but introduces a different practical constraint: fresh allograft tissue must be implanted within approximately 28 days of procurement to preserve chondrocyte viability. This narrows the scheduling window and is simply a logistical reality of working with living donor tissue.

Recovery timelines also differ meaningfully. OCA typically involves six to eight weeks of protected weight-bearing and requires roughly four months longer to reach full activity than OATS, whose autograft plug integrates more quickly. Both procedures are single-stage — an advantage they share over two-stage techniques such as ACI or MACI, which require a separate biopsy appointment before the repair operation.

Neither recovery profile is inherently preferable; some patients may weigh a slower return to activity against the absence of donor-site risk, and others the reverse.

What the outcomes evidence shows

Long-term follow-up data offer a reassuring headline: when each procedure is used for the right indication, secondary surgery rates at ten years are not significantly different. In a 2022 analysis (Burroughs et al.), OCA patients required further surgery at a rate of 23.9% compared with 21.9% for OATS — a gap that did not reach statistical significance, suggesting comparable durability when selection criteria are properly applied.

Graft survivorship for OCA specifically runs to approximately 78% at ten years in a 2026 conditional survivorship analysis (Linstrom et al.); an earlier series placed figures at 82.6% at five years and 69.6% at ten years, with 68% of grafts still in situ and functioning at a mean follow-up of 12.9 years. These ranges reflect genuine variability across patient profiles and defect characteristics rather than contradictory data.

Functional outcomes across techniques

A 2024 systematic review and meta-analysis — 47 studies, 1,993 patients, mean follow-up of 57.2 months — found that OATS, OCA, ACI, and MACI all produced significant improvements in IKDC, Lysholm, Tegner, and VAS scores for tibiofemoral cartilage defects. No single technique proved universally superior. In paediatric populations, OCA showed the lowest failure rates for larger defects, while OATS outperformed microfracture on radiographic repair scores and return-to-sport outcomes.

The evidence gap — and why it matters less than it might seem

Direct head-to-head randomised trials comparing OATS and OCA in the knee are scarce; the evidence base rests largely on cohort studies, registry analyses, and expert consensus. That limitation is real, but it does not undermine the clinical framework outlined in earlier sections. The size thresholds and modifying factors — subchondral bone loss, prior surgery, joint alignment — are grounded in consistent biological rationale and broad expert agreement across published series, even where formal comparative trial data are absent. The absence of a declared winner across all patients reflects the genuinely lesion-specific nature of this decision, not a gap in understanding.